Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma

NCT03777657 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

997

Enrollment

INDUSTRY

Sponsor class

Conditions

Gastric, or Gastroesophageal Junction Adenocarcinoma

Interventions

DRUG: Tislelizumab
DRUG: Placebo
DRUG: Cisplatin
DRUG: Oxaliplatin
DRUG: Capecitabine
DRUG: 5-Fluorouracil

Sponsor

BeiGene